Pralatrexate

drugbox
IUPAC_name = "N"- [4- [1- [(2,4-Diamino-6-pteridinyl)methyl] - 3-butynyl] benzoyl] -L-glutamic acid

---

CAS_number = 146464-95-1
ATC_prefix =
ATC_suffix =
PubChem = 725808
DrugBank =
C = 23 | H = 23 | N = 7 | O = 5
molecular_weight = 477.47 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Intravenous

Pralatrexate (rINN), also known as 10-propargyl-10-deazaaminopterin, common name PDX, is a drug candidate being studied for the treatment of cancer. PDX is a folate analog inhibitor of dihydrofolate reductase. As of August 2008, it is undergoing Phase II clinical trials for the treatment of Hodgkin and non-Hodgkin lymphoma (including T-cell lymphoma), non-small cell lung cancer (NSCLC), and bladder cancer.

Results in non-small cell lung cancer appear promising. [cite journal |author=Krug LM, Azzoli CG, Kris MG, "et al" |title=10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer |journal=Clin. Cancer Res. |volume=9 |issue=6 |pages=2072–8 |year=2003 |month=June |pmid=12796370 |doi= |url=http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=12796370]

References

External links

* [http://www.clinicaltrials.gov/ct2/results?term=pralatrexate Clinical trials of pralatrexate] at ClinicalTrials.gov
* [http://www.allos.com/index.cfm?p2=26014210&category1=prod&category2=pdx&category3=x&category4=x&category5=x&category6=x Allos Therapeutics Information on PDX]